Medullary thyroid carcinoma: importance of serial serum calcitonin measurement
This mirrors whats seen in other chronic pain conditions associated with obesity
The window of highest risk is generally the first two to four weeks after a dose increase
So obesity and diabetes and certain other conditions are also associated with what we call a low-grade inflammation, and that is being accused of being responsible for some of, or a lot of, the problems that we have in metabolic disease, and that's where GLP-1 has this very pronounced effect on this low-grade inflammation and really puts it down
Glucagon: the energy-expenditure dial Glucagon-receptor agonism is retatrutides distinguishing third lever
Tirzepatide reduces it disproportionately which is why the metabolic improvements seen in the SURPASS diabetes trials, including HbA1c reductions of 2.02.3%, were among the largest ever documented for any antidiabetic medication